11
Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)
Condition(s):Diabetic Peripheral Neuropathic PainLast Updated:February 10, 2017Terminated
Ranexa: 87 Clinical Trials, Page 2 of 9
Hide Studies Not Open or Pending
12
Ranolazine, Ethnicity and the Metabolic Syndrome
Condition(s):Coronary Artery Disease; Angina; Metabolic SyndromeLast Updated:July 11, 2013Unknown status
13
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)
Condition(s):AnginaLast Updated:February 7, 2017Unknown status
14
Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy
Condition(s):HCM – Hypertrophic Non-Obstructive CardiomyopathyLast Updated:December 10, 2020Completed
15
Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion
Condition(s):Atrial FibrillationLast Updated:April 27, 2017Terminated
16
Ranolazine in Ischemic Cardiomyopathy
Condition(s):Cardiomyopathy; Chest Pain; DyspneaLast Updated:March 4, 2020Completed
17
A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
Condition(s):Dilated CardiomyopathyLast Updated:May 8, 2014Unknown status
18
Ranolazine for the Treatment of Chest Pain in HCM Patients
Condition(s):Hypertrophic CardiomyopathyLast Updated:March 3, 2017Completed
19
Ranolazine and Microvascular Angina by PET in the Emergency Department
Condition(s):Microvascular AnginaLast Updated:May 16, 2017Completed
20
Ranolazine a Potential New Therapeutic Application
Condition(s):Myocardial StunningLast Updated:February 25, 2021Withdrawn